Is Moderna's New Vaccine the Answer to the Highly Mutated BA.2.86 COVID-19 Variant?
Portfolio Pulse from Vandana Singh
Moderna Inc's updated COVID-19 vaccine has shown an 8.7-fold increase in neutralizing antibodies against the highly mutated BA.2.86 variant, according to clinical trial data. The vaccine is pending FDA approval for the fall 2023 vaccination season. The Centers for Disease Control (CDC) suggests that updated vaccines may be effective in reducing severe disease and hospitalization caused by this variant. Moderna's shares are up 0.76% in the premarket session.
September 06, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's updated COVID-19 vaccine shows promising results against the BA.2.86 variant. The vaccine is pending FDA approval for the fall 2023 vaccination season. This news has led to a 0.76% increase in Moderna's premarket shares.
The promising results from Moderna's updated COVID-19 vaccine against the BA.2.86 variant have likely contributed to the increase in the company's premarket shares. If the vaccine receives FDA approval, it could potentially lead to further increases in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100